Categories
MedTech Pharma Marketing

Omnichannel vs Traditional Healthcare Marketing: Key Differences Explained 2025

FAQ #2: How Does Omnichannel Marketing Differ from Traditional Marketing in Healthcare?

The fundamental difference between omnichannel and traditional healthcare marketing lies in customer-centricity versus channel-centricity. Traditional marketing approaches often prioritize product promotion through isolated channels, while omnichannel marketing focuses on creating integrated customer journeys that provide value at every touchpoint.1

Traditional Healthcare Marketing Characteristics:

  • Channel silos operating independently with minimal integration
  • One-size-fits-all messaging across different platforms
  • Product-focused communication rather than customer needs
  • Limited data sharing between different marketing activities
  • Reactive approach to customer interactions

Omnichannel Healthcare Marketing Characteristics:

  • Integrated channels that share data and insights
  • Personalized messaging tailored to individual customer profiles
  • Customer journey focus addressing specific needs at each stage
  • Real-time data utilization across all touchpoints
  • Proactive engagement based on predictive analytics

The shift represents moving from “spray and pray” tactics to precision targeting. For example, instead of sending identical product information to all cardiologists, an omnichannel approach would deliver personalized content based on each physician’s specialty focus, previous interactions, and current patient demographics.2

Healthcare professionals increasingly expect digital-first interactions. The pandemic accelerated this transformation, with HCPs now demanding timely, appropriate, and digitally-led communication. Research shows that 65% of HCPs complain about pharma “spam” where products are pushed repeatedly, highlighting the need for more sophisticated, value-driven engagement strategies.3

The customer experience benefits are significant:

  • 6x to 8x better response rates when personalized emails precede face-to-face meetings1
  • 88% of HCPs say they’d be twice as likely to meet with representatives after positive digital interactions3
  • 23% increase in campaign effectiveness when sales and marketing are synchronized1

This transformation requires pharmaceutical and medical device companies to break down traditional silos between sales, marketing, medical affairs, and market access teams. The result is a more coordinated, customer-centric approach that drives better outcomes for both companies and healthcare providers.4

This is a part of The Complete Guide to Omnichannel Marketing in Pharma and Medtech series.

This content has been enhanced with GenAI tools.

Read other series:

Scaling MedTech: From Product to Market

SaMD Europe Launch Guide

Categories
MedTech Pharma Marketing

What is Omnichannel Marketing in Pharma & Medtech? Complete Definition Guide 2025

FAQ #1: What is Omnichannel Marketing in Pharma and Medtech?

Omnichannel marketing in pharmaceutical and medical device industries is a customer-centric approach that integrates multiple communication channels to create seamless, personalized experiences for healthcare professionals (HCPs), patients, and other stakeholders. Unlike traditional multichannel marketing where channels operate independently, omnichannel marketing connects digital and physical touchpoints into a unified ecosystem that recognizes users across their entire healthcare journey.1

The core principle involves using interconnected channels that work together to enhance customer experience and engagement. Each channel is optimized and working in harmony to provide consistent messaging while allowing for channel-specific customization. This includes everything from email marketing and social media to in-person sales visits, webinars, and mobile applications.2

Key characteristics that distinguish omnichannel from multichannel approaches include:

  • Unified customer data across all touchpoints
  • Consistent brand messaging with channel-appropriate customization
  • Seamless transitions between different interaction points
  • Personalized content based on individual customer profiles
  • Cross-channel insights that inform future interactions

For medical device companies, this means creating cohesive messaging across various platforms to boost engagement and conversions. The approach enables companies to reach healthcare professionals wherever they are, regardless of their preferred communication channel, while maintaining consistency in brand experience.3

Studies show that omnichannel personalization can halve acquisition costs, increase marketing budget efficiency by 10% to 30%, and increase revenue by 5% to 15%. This significant impact explains why 98% of pharmaceutical executives emphasize the importance of implementing an omnichannel strategy for their organizations.4,5,6

This is a part of The Complete Guide to Omnichannel Marketing in Pharma and Medtech series.

This content has been enhanced with GenAI tools.

Read other series:

Scaling MedTech: From Product to Market

SaMD Europe Launch Guide

Categories
MedTech Pharma Marketing

Navigating MLR with AI

What is MLR and why does it matter in pharma and MedTech marketing?

MLR stands for Medical, Legal and Regulatory review. It is a mandatory, cross-functional process that ensures that all promotional, educational and informational materials are:

  • accurate and balanced
  • scientifically substantiated
  • compliant with global and local regulations

In highly regulated industries like pharmaceuticals and MedTech, MLR approval is a critical checkpoint before any HCP-facing or public content goes live. Failure to follow MLR requirements can result in:

  • Regulatory penalties
  • Product delistings
  • Legal liabilities
  • Damaged reputation

As content volume increases with the rise of omnichannel and AI-generated materials traditional MLR workflows can become a bottleneck unless modernized.

How can AI improve MLR workflows?

AI supports MLR processes in three major ways:

1. Content Pre-Screening

AI tools can scan drafts to:

  • Flag non-compliant language
  • Identify missing references or claims
  • Highlight risky phrasing (e.g., off-label implications)

This allows compliance teams to focus human review where it’s most needed, accelerating the overall review cycle.

2. Co-Pilots for MLR Teams

AI-powered assistants can:

  • Suggest alternative compliant language
  • Autofill references from approved claim libraries
  • Surface similar approved content as templates

These tools significantly reduce manual effort, especially during content revisions.

3. Approval of Modular Content

The modular content model breaks content into pre-approved blocks. AI can then:

  • Assemble high-volume personalized content on demand
  • Guarantee compliance by combining only validated modules
  • Eliminate hallucination risk (a common issue with generative AI)

This method not only accelerates content production but also reduces MLR review time by up to 60%.

How does AI integrate into the MLR approval chain?

Phase AI Role Benefit

PhaseAI RoleBenefit
Pre-MLRDrafting, tone adjustment, auto-translationFaster initial content creation
MLR ReviewPre-screening, red-flagging issues, checking against literature referencesPrioritizes human review efficiently
Post-MLR DeploymentMatching with HCP profiles, tagging usageTracks content reuse & optimization

The AI’s involvement must be transparent, traceable, and auditable, ensuring compliance with internal SOPs and external guidelines.

What are the risks and limitations of AI in MLR?

While AI accelerates MLR processes, there are important caveats:

  • Hallucinations: Generative AI may invent plausible-sounding but false claims. Limiting AI to assembly of approved blocks solves this.
  • Regulatory uncertainty: Global health authorities (e.g., FDA, EMA) have not yet fully defined how AI-assisted content creation fits within promotional regulations.
  • Tool validation: Any AI tool used must undergo proper validation, risk assessment, and documentation — especially in GxP environments.

Best practices for AI-driven MLR transformation

  • Separate AI use by stage
    • Use generative AI only before MLR to assist with content ideation or rephrasing.
    • Use only pre-approved content for AI assembly after MLR.
  •  Invest in modular content strategy
    • Pre-approve reusable content blocks to scale faster without repeated review cycles.
  •  Enable “compliance by design”
    • Integrate claim libraries, brand guardrails, and reference checkers directly into content tools.
  • Improve the supply chain, not just speed
    • Faster content creation is meaningless without scalable MLR capacity.
  •  Partner with experienced vendors
    • Choose platforms and agencies that specialize in life sciences compliance and can demonstrate audit readiness.

Summary

Modern MLR is no longer just a gatekeeper. MLR process is a strategic enabler of fast, scalable, and compliant pharma marketing. When powered responsibly by AI, it can cut approval cycles from weeks to days, support omnichannel campaigns, and free up expert reviewers for higher-value tasks.

The future of compliant content in life sciences is modular, AI-assisted, and human-supervised — and it’s already underway.

This text has been enganced with GenAI tools.

Categories
MedTech Pharma Marketing

Top Use Cases of AI in Pharma & MedTech

What are the main forms of generative AI being leveraged in pharma marketing?

Generative AI can be categorized into three general uses:

  • Content Generators: These produce texts, images, and video rapidly, and can also refine content by changing tone, simplifying information, or fine-tuning messages for specific audience segments.
  • Answer Engines: These are new forms of ‘search’ that generate direct answers (text, images, video) rather than just providing links. They can be used to extract insights from market research reports or summarize clinical studies.
  • Agents (Large Action Models – LAMs): These forms of AI act to achieve specific goals without specific instructions or human oversight. For example, an AI agent could review keynote Q&As and social media reactions to assess the medical community’s response to a drug launch. These are considered the most controversial due to their autonomous nature.

What are the primary use cases for AI in pharma and MedTech marketing?

There are four broad categories of AI use cases in pharma and MedTech marketing:

  1. Strategic Insights Generation: AI can analyze vast amounts of both structured (e.g., CRM data) and unstructured data (e.g., government policy documents, articles on HCP preferences) to generate actionable insights and trends. This can improve understanding by up to 30%. However, caution is advised as AI can produce plausible but incorrect results (“AI hallucination”).
  2. Marketing Content Generation: AI is crucial for omnichannel strategies that require high content volume for personalization. It can rapidly generate various content formats (texts, images, video, audio) and reduce content creation costs by 30-50%.
  3. MLR Acceleration (Medical, Legal, Regulatory Review): AI can modernize labor-intensive MLR processes, which typically take 21 to 56 days for approval. AI tools can pre-screen materials, flagging problematic content for detailed review and fast-tracking compliant assets. AI co-pilots can also assist MLR staff with referencing claims and rephrasing options, potentially accelerating content approvals two to three times.
  4. Field Force Enablement: AI benefits customer-facing staff like sales teams and Medical Science Liaisons (MSLs) by improving training, account planning, and content delivery. AI can provide immediate access to drug information, offer coaching for specific situations, and integrate with CRM to help reps prioritize accounts and personalize HCP engagements based on “next best” message or format recommendations.
Categories
Pharma Marketing

Understanding AI in Pharma Marketing

What is Artificial Intelligence (AI) in a pharma commercial context?

In a pharma commercial context, AI primarily refers to generative AI, which differs from traditional “classical AI” or machine learning.

  • Classical AI / Machine Learning models perform specific tasks, like analyzing data for predictions or identifying patient groups, using very specific datasets.
  • Generative AI works with a foundational, large language model (LLM) trained on vast amounts of data, enabling it to be applied to many different problems. Its key characteristics include:
    •   Basic competences applicable to various problems.
    •   Ability to learn from structured and unstructured data.
    •   Generation of multiple outputs such as texts, images, speech, video, and designs.
    •     An intuitive, conversational user interface.

In pharma, generative AI is used for activities like writing marketing materials, generating webinars, building image and video libraries, spotting segmentation opportunities, and speeding up marketing processes. It is projected to grow faster in healthcare than any other industry, potentially generating between $60 billion and $110 billion a year in economic value for the pharma and MedTech industries, with most value going to commercial operations.

Categories
MedTech Pharma Marketing

Multichannel vs Omnichannel in Pharma Marketing

What is the difference between multichannel and omnichannel marketing in pharma and MedTech?

Multichannel marketing uses multiple independent channels (like television, social media, email, websites) to communicate with customers. In this approach, channels often operate as silos, repeating the same message, with the focus remaining on the product rather than the user. It lacks a connecting node between channels.


Omnichannel marketing also engages multiple channels, but they are all integrated and coordinated to provide a unified, seamless, and personalized experience for the customer, who is placed at the center of the marketing funnel. This approach ensures that information is available precisely when needed, encourages deeper content exploration, and reinforces messages across touchpoints, ultimately improving engagement and fostering trust.

According to McKinsey, correctly implemented omnichannel models can lead to 5-10% revenue growth and 10-20% marketing efficiencies and cost savings for pharma companies.

Categories
MedTech Pharma Marketing

Digital marketing in MedTech and Pharma

Is digital marketing in MedTech and Pharma similar? Understanding the specifics of MedTech and Digital Health digital marketing is essential to success.

MedTech digital marketing

The four main components of digital marketing in the medical devices industry are digital strategy consulting, digital content creation and management, digital campaign execution, and analytics.

  • Digital Marketing Consulting involves helping MedTech companies assess their priorities and strengths, optimize their operations and innovation, and develop effective go-to-market strategies.
  • Digital content creation and management involves producing engaging and informative content for various channels such as email, social media, blogs, webinars, etc. that showcase medical devices’ value proposition and benefits.
  • Digital campaign execution involves designing and implementing marketing campaigns that target specific segments of healthcare professionals (HCPs) or patients using digital tools such as CRM systems, marketing automation platforms, SEO/SEM techniques, etc.
  • Digital analytics involves measuring and evaluating the performance and impact of digital marketing activities using data-driven methods such as web analytics, customer feedback surveys, ROI calculations, etc.

Digital consulting is a vital component of digital marketing for medical devices and should be a first step. It helps MedTech companies to:

  • Define their vision and goals for digital transformation
  • Assess their current capabilities and gaps
  • Develop a roadmap and action plan for implementing digital solutions
  • Align their organization and culture with digital best practices

Digital marketing of medical devices in comparison to pharmaceuticals

Digital marketing for Medical Devices in many aspects is similar to the pharmaceutical industry, however, there are significant differences.

What are the similarities between MedTech and Pharma digital marketing?

  • Both Pharma and MedTech use digital tools to inform and influence HCPs and patients about their products and services.
  • Both industries rely on data and analytics to measure and optimize their digital marketing activities.
  • Medical Devices face regulatory challenges and compliance issues when engaging with their audiences online that are similar to those in pharmaceuticals.

The key differences between Pharma and Medical Devices digital marketing are that:

  • Medtech companies tend to have more complex products that require more technical expertise and demonstration than pharma companies.
  • Medtech companies have a wider range of stakeholders to consider, such as hospital administrators, payers, distributors, etc. than pharma companies.
  • Medtech companies have more opportunities to leverage digital health and digital therapeutics (DTx), such as connected devices, apps, sensors, etc. that can enhance their value proposition and customer experience than pharma companies

Outsourcing digital marketing services in the MedTech industry

Medical device companies may look for different services or support when deciding to outsource digital marketing, depending on their needs and goals.

Some possible services or support are:

  • Quality assurance: ensuring that the digital marketing activities comply with regulatory standards and best practices.
  • Content production and management: producing digital content or products such as websites, apps, videos, etc. that showcase the features and benefits of medical devices.
  • E-commerce: setting up and managing online platforms that allow customers to order and purchase medical devices easily and securely.
  • Virtual sales channels: creating and maintaining digital tools that enable sales reps to communicate and demonstrate medical devices to HCPs remotely.
  • Data analytics: collecting and analyzing data from digital marketing activities to measure performance, optimize campaigns, and generate insights

Generally, smaller MedTech companies may need more comprehensive and flexible services and support than larger companies, as they may have less experience and capacity for digital marketing. Larger companies may need more specialized and customized support than smaller companies, as they may have more complex and diverse needs for digital marketing.

Some possible factors that influence digital marketing service requirements are:

  • The type and complexity of medical devices that the company produces or sells.
  • The level of expertise and resources that the company has internally for digital marketing.
  • The scope and scale of digital marketing activities that the company wants to undertake.
  • The budget and timeline that the company has for digital marketing outsourcing.

The skillset of MedTech digital marketer

Some of the skills of a digital marketing expert from pharma are transferrable to provide medical device digital marketing services too. For example, both sectors require:

  • Knowledge of regulatory requirements and compliance standards.
  • Ability to create engaging and informative content for different audiences and channels.
  • Proficiency in using various digital tools and platforms to design, execute, and measure campaigns.

However, there are also some differences between pharma and medical device digital marketing that may require additional skills or adaptation. The key differences are that:

  • Medical device customers have different expectations and needs than pharma customers. They may be more interested in product features, benefits, demonstrations, or testimonials than in disease mechanisms or outcomes.
  • Medical devices are more diverse and complex than drugs. They can range from tissue grafts to prostheses to digital devices and apps. They may also have different modes of action, indications, or usage scenarios.
  • Medical devices may have shorter product life cycles than drugs. They may face more competition or innovation from other players in the market. They may also require more frequent updates or upgrades.

Therefore, a digital marketing expert to excel in the Medical Devices industry may need to understand the nuances of device marketing and how to tailor their strategies accordingly. MedTech digital marketing specialist has to learn about the specific types of devices they are marketing and how they work, who they serve, and what value they offer. Finally, digital marketer in MedTech industry has to be flexible and agile in responding to changing market conditions and customer feedback.

Regulatory requirements for medical device digital marketing

Regulatory requirements for medical device digital marketing vary depending on the type of device, the market, and the channel. Some of the general requirements are:

  • Medical device digital marketing must be truthful, accurate, and not misleading.
  • Medical device digital marketing must comply with the relevant laws and regulations of each country or region where they operate.
  • Medical device digital marketing must respect the data privacy and security of customers and users.

Some examples of specific regulatory requirements for medical device digital marketing are:

  • The Medical Devices Regulation (MDR) applies since 26 May 2021 in the European Union. It sets out new rules for placing medical devices on the market, including requirements for clinical evidence, post-market surveillance, labeling, and advertising.
  • The In Vitro Diagnostic Devices Regulation (IVDR) applies since 26 May 2022 in the European Union. It replaces Directive 98/79/EC and introduces new classification rules, conformity assessment procedures, performance evaluation requirements, etc. for in vitro diagnostic devices.
  • The Food and Drug Administration (FDA) provides guidance documents with digital health content for medical device manufacturers in the United States. They cover topics such as software as a medical device, mobile medical applications, clinical decision support software, cybersecurity, artificial intelligence/machine learning, etc.

Read our Expert Guide for 2025: Medical Device Digital Marketing

Categories
Pharma Marketing

ACI’s Digital Marketing in Healthcare

On the 26th and 27th of October in London, I had the pleasure of participating in the ACI’s Digital Marketing in Healthcare Conference. This relatively small event has gathered an unusual, interesting set of speakers and guests coming not only from the pharmaceutical industry and its vendors.

Tom Macfarlane (Accenture) speaks at ACI Digital Marketing in Healthcare Conference, London 2016


As it often happens on such occasions, I have particularly enjoyed conversations over coffee outside of the conference room. It has been a pleasure to meet and talk to:

  • Simeon Mellor [@MellorSimeon] from AstraZeneca (on digitalisation of procurement and shared services in Poland)
  • Caryn Kavovit and Linda Bew from London office of WebMD (on disease awareness campaigns and differences between US and UK market)
  • Ann-Charlotte Beckman running the Swedish Netdoktor (great stories on disease awareness campaigns for Pfizer’s Viagra)
  • Nicole Ferguson from Iq Digital Media Marketing (on content marketing in Germany and Switzerland)
  • Rob Wyer [@robwyer] from Swii.ch (on measuring and impacting behavioural changes via digital channels)
  • Yamelis Figueredo from BMS (on challenges of global versus local approach to digital marketing in pharmaceutical industry

Of course, this does not mean that presentations were not valuable. Due to Chiltern Railway’s failure I have not been able to hear highly appreciated presentation of NHS’ Head Of Digital Primary Care Development, Tracy Grainer [@tracey_grainger].
I have enjoyed a comprehensive review of digital space in healthcare by Tom Macfarlane [@tomwmacfarlane], Director and Lead of IDMP offering in Accenture Life Sciences. Tom has touched on all critical points in the current discussions on digital marketing in healthcare. Patient engagement, regulatory environment, technological advancements of EHR and IOT/QS. Very dense, highly engaging presentation.
I have been lucky to share the panel with two great speakers. Looking at their biographies one could expect them to confront each other:
A disrupting future personalised by Dr Tobias D. Gantner, CEO and Founder of HealthCare Futurist who genuinely hacks the healthcare industry to make the future happen now. Tobias gave us some feel of Steve Jobs reality distortion with his ideas such as a wifi connected baby pacifier filled with temperature and pressure sensors and enabled with paracetamol ejection device.
A traditional, sales-driven approach of Dr Graham Leask, a pharma executive with 20 years of experience in pharmaceutical sales and marketing, now a marketing strategy lecturer at Aston University in Birmingham. Well, experienced does not mean being backwards or conservative. Dr Leask has actually preached the same multichannel, measurable, digitally enabled approach to marketing as offered by the author of this text.
The same story has been told over again by Anders Tullgren, President of Intercontinental Markets in BMS and Carmen Chavarri running Digital for Neuroscience franchise of Shire in Spain. Uri Goren from Teva has opened an interesting topic of using digital channels to crowdsource healthcare solutions with patient advocacy groups.
I have left ACI’s Digital Marketing in Healthcare Conference feeling that the industry as a whole has finally embraced digital channels. Whether it is Chloe Wates‘ selection of speakers or just a reality of today? What are your thoughts?

Categories
Pharma Marketing

(Not) The Best Pharmaceutical Ads – Lions Healthcare 2016

Lions Healthcare 2016 Awards for the best pharmaceutical advertising have been announced.  See the winners.
As every year, what they show is that pharma advertising lacks creativity. What is more important, 2016 Lions Healthcare Pharma winners are not those most efficient in conveying the message and changing prescription behaviors.
Lions Healthcare is a contest made by agencies and for agencies. Looking at the winners, but also at the shortlist of submission it is clear that agencies have no idea how to operate in regulated markets. They are creative while talking to general public, on disease awareness or about medical devices.
When it comes to branded, promotional communication directed to healthcare professionals pharma marketers are on their own. Or they get offered a dead fish, which has been a winner in 2015.

Cannes Lions 2015


In the 2016 Lions Healthcare Awards, no agency has been able to get a prize for creativity while providing multichannel content that is fact-based and scientifically proven. Oh, well, indeed – McCann has made some disgusting posters for Pfizer’s Xalatan,  get the prize, and left us not impressed, again.
Does it mean that advertising agencies are creative only when they can lie or stretch facts? Is it really too hard to clearly state the advantages of pharmaceutical products that extend or save lives? Somehow, hundreds of pharma marketers and thousands of sales reps are able to produce and convey such messaging every day. Is it bland? Maybe. We are still waiting for agency content that would be both creative and at the same time compliant. Saying that, please take a look at the 2016 Lions Healthcare Grand Prix and Gold Lions below.

GRAND PRIX – LIONS HEALTHCARE 2016

BREATHLESS CHOIR – PHILIPS

A Breathless Choir | Presented by Philips


By: OGILVY & MATHER LONDON
Category: PHARMA >  COMMUNICATIONS TO NON-HEALTHCARE PROFESSIONALS > DEVICES & DIAGNOSTICS

GOLD – LIONS HEALTHCARE 2016

THE NAZAR INITIATIVE – ASTER HEALTHCARE

Aster’s The Nazar Initiative


By: THE CLASSIC PARTNERSHIP ADVERTISING
Category: PHARMA >  PHARMA COMMUNICATIONS TOOLS & DEVICES > HCP DEVICES & DIAGNOSTICS

GOLD – CAMPAIGN AWARD – LIONS HEALTHCARE 2016

GAMEBOY/STUDENT/PAINTER – PFIZER CORPORATION HONGKONG



By: McCANN HEALTH
Category: PHARMA > COMMUNICATIONS TO NON-HEALTHCARE PROFESSIONALS > PHARMA, VACCINES & BIOTECH – BRANDED COMMUNICATION

GOLD – LIONS HEALTHCARE 2016

LAST WORDS – INDIAN ASSOCIATION OF PALLIATIVE CARE (IAPC)

#LastWords IAPC


By: MEDULLA COMMUNICATIONS
Category: PHARMA > COMMUNICATIONS TO HEALTHCARE PROFESSIONALS > EDUCATION & AWARENESS
 

Categories
Digital Health MedTech Pharma Marketing

MoovCare – a clinically proven mHealth app in lung cancer treatment

MoovCare, a mHealth app to help patients with lung cancer presented at the annual American Society of Clinical Oncology (ASCO) meeting.

moovcare on tablet
MoovCare tablet interface

An Israeli company Sivan Innovation and the Cancer Institute of Western France are behind MoovCare – a mHealth application presented at the ASCO annual meeting in Chicago.


MoovCare claims to be the first application of its kind. It allows controlling lung cancer treatment based on reports on outcomes submitted by patients via web or mobile-connected devices. It enables the early identification of relapse or complications requiring rapid and specific care.
According to the clinical data from the III phase randomized study on 300 patients as presented at ASCO, this mHealth application provides direct benefit in terms of prolonged survival.


The main advantage of using the app in lung cancer therapy is early detection of relapse, which is symptomatic and typical for lung cancer. This allows optimal treatment and in turn increases of survival rate among patients.


An additional effect of the app is improved treatment compliance (observance of scheduled visits, lower number of inopportune phone calls, lower number of imaging). All this at a comparatively very low cost of less than 10 000 USD versus 265 000 USD per one CT-scan for Lung Cancer.

How does MoovCare work?

MoovCare mHealth app lung cancer Mode of Action – Sivan Innovation
MoovCare mHealth app lung cancer Mode of Action – Sivan Innovation


MoovCare is being “prescribed” to ambulatory patients. Patients are asked to fill in the web-based form each week, self-assessing 12 clinical parameters and having a free text field to enter any information they consider of importance. Data are securely passed and processed within the application. An algorithm behind MoovCare analyses the data provided and in case of any anomaly detected reports it to the oncologist and hospital dashboard. Based on the alert from Moovcare healthcare providers can contact patients and take any necessary action.
Company and research behind MoovCare.


MoovCare is a product of Sivan Innovation. Founded in 2014 in Jerusalem by Daniel Israel, Sivan Innovation is an Israeli E-health start-up and R&D company.

The research presented at ASCO has been conducted by Dr. Fabrice Denis at the Cancer Institute of Western France


MoovCare is a perfect example of how digital innovation, mHealth, and IoT trends are positively impacting healthcare and patient outcomes. We look forward to seeing more of such innovations coming not only from startups such as Sivan innovation but also from Big Pharma companies with their vast R&D resources.